Pharmacokinetics of Cannabidiol, Cannabidiolic Acid, Δ9-Tetrahydrocannabinol, Tetrahydrocannabinolic Acid and Related Metabolites in Canine Serum After Dosing With Three Oral Forms of Hemp Extract
Open Access
- 4 September 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Veterinary Science
Abstract
Cannabidiol (CBD)-rich hemp extract use is increasing in veterinary medicine with little examination of serum cannabinoids. Many products contain small amounts of Δ9-tetrahydrocannabinol (THC), and precursor carboxylic acid forms of CBD and THC known as cannabidiolic acid (CBDA) and tetrahydrocannabinolic acid (THCA). Examination of the pharmacokinetics of CBD, CBDA, THC, and THCA on three oral forms of CBD-rich hemp extract that contained near equal amounts of CBD and CBDA, and minor amounts (<0.3% by weight) of THC and THCA in dogs was performed. In addition, we assess the metabolized psychoactive component of THC, 11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-THC) and CBD metabolites 7-hydroxycannabidiol (7-OH-CBD) and 7-nor-7-carboxycannabidiol (7-COOH-CBD) to better understand the pharmacokinetic differences between three formulations regarding THC and CBD, and their metabolism. Six purpose-bred female beagles were utilized for study purposes, each having an initial 7-point, 24-h pharmacokinetic study performed using a dose of 2 mg/kg body weight of CBD/CBDA (~1 mg/kg CBD and ~1 mg/kg CBDA). Dogs were then dosed every 12 h for 2 weeks and had further serum analyses at weeks 1 and 2, 6 h after the morning dose to assess serum cannabinoids. Serum was analyzed for each cannabinoid or cannabinoid metabolite using liquid chromatography and tandem mass spectroscopy (LC-MS/MS). Regardless of the form provided (1, 2, or 3) the 24-h pharmacokinetics for CBD, CBDA, and THCA were similar, with only Form 2 generating enough data above the lower limit of quantitation to assess pharmacokinetics of THC. CBDA and THCA concentrations were 2- to 3-fold higher than CBD and THC concentrations, respectively. The 1- and 2-week steady-state concentrations were not significantly different between the two oils or the soft chew forms. CBDA concentrations were statistically higher with Form 2 than the other forms, showing superior absorption/retention of CBDA. Furthermore, Form 1 showed less THCA retention than either the soft chew Form 3 or Form 2 at weeks 1 and 2. THC was below the quantitation limit of the assay for nearly all samples. Overall, these findings suggest CBDA and THCA are absorbed or eliminated differently than CBD or THC, respectively, and that a partial lecithin base provides superior absorption and/or retention of CBDA and THCA.Keywords
This publication has 38 references indexed in Scilit:
- Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological FluidCannabis and Cannabinoid Research, 2016
- Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in TherapyCannabis and Cannabinoid Research, 2016
- The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a reviewVeterinarni Medicina, 2016
- Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nauseaPsychopharmacology, 2015
- Pharmacokinetic and Pharmacodynamic Profile of Supratherapeutic Oral Doses of Δ9‐THC in Cannabis UsersThe Journal of Clinical Pharmacology, 2013
- Heat Exposure ofCannabis sativaExtracts Affects the Pharmacokinetic and Metabolic Profile in Healthy Male SubjectsPlanta Medica, 2012
- Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herbTrends in Pharmacological Sciences, 2009
- Cannabidiolic Acid as a Selective Cyclooxygenase-2 Inhibitory Component in CannabisDrug Metabolism and Disposition, 2008
- Comparative metabolism of cannabidiol in dog, rat and manPharmacology Biochemistry and Behavior, 1991
- Disposition and Bioavailability of Various Formulations of Tetrahydrocannabinol in the Rhesus MonkeyJournal of Pharmaceutical Sciences, 1985